177 related articles for article (PubMed ID: 32180369)
1. Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
Ogyu K; Noda Y; Yoshida K; Kurose S; Masuda F; Mimura Y; Nishida H; Plitman E; Tarumi R; Tsugawa S; Wada M; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
Neuropsychopharmacol Rep; 2020 Jun; 40(2):138-149. PubMed ID: 32180369
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study.
Citrome L; Walling DP; Zeni CM; Starling BR; Terahara T; Kuriki M; Park AS; Komaroff M
J Clin Psychiatry; 2020 Dec; 82(1):. PubMed ID: 33326711
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
[TBL] [Abstract][Full Text] [Related]
4. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
Buchanan RW; Panagides J; Zhao J; Phiri P; den Hollander W; Ha X; Kouassi A; Alphs L; Schooler N; Szegedi A; Cazorla P
J Clin Psychopharmacol; 2012 Feb; 32(1):36-45. PubMed ID: 22198451
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.
Potkin SG; Phiri P; Szegedi A; Zhao J; Alphs L; Cazorla P
Schizophr Res; 2013 Nov; 150(2-3):442-9. PubMed ID: 24075603
[TBL] [Abstract][Full Text] [Related]
6. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
[TBL] [Abstract][Full Text] [Related]
7. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
Ruberg SJ; Chen L; Stauffer V; Ascher-Svanum H; Kollack-Walker S; Conley RR; Kane J; Kinon BJ
BMC Psychiatry; 2011 Feb; 11():23. PubMed ID: 21306626
[TBL] [Abstract][Full Text] [Related]
8. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
Leucht S; Zhao J
J Psychopharmacol; 2014 Apr; 28(4):387-94. PubMed ID: 24429222
[TBL] [Abstract][Full Text] [Related]
9. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
Szegedi A; Verweij P; van Duijnhoven W; Mackle M; Cazorla P; Fennema H
J Clin Psychiatry; 2012 Dec; 73(12):1533-40. PubMed ID: 23290326
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.
Kinoshita T; Bai YM; Kim JH; Miyake M; Oshima N
Psychopharmacology (Berl); 2016 Jul; 233(14):2663-74. PubMed ID: 27271087
[TBL] [Abstract][Full Text] [Related]
11. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM
Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
13. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
Landbloom R; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
CNS Spectr; 2017 Aug; 22(4):333-341. PubMed ID: 27821210
[TBL] [Abstract][Full Text] [Related]
14. Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.
Kumagai F; Suzuki T; Fleischhacker WW; Yasui-Furukori N; Mimura M; Uchida H
J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549487
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
Potkin SG; Cohen M; Panagides J
J Clin Psychiatry; 2007 Oct; 68(10):1492-500. PubMed ID: 17960962
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
Liu-Seifert H; Osuntokun OO; Feldman PD
Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
[TBL] [Abstract][Full Text] [Related]
17. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
[TBL] [Abstract][Full Text] [Related]
18. Divergence of dose-response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study.
Takekita Y; Hiraoka S; Iwama Y; Sunada N; Aoki N; Ogata H; Funatsuki T; Takano C; Yanagida T; Koshikawa Y; Naito M; Yamamoto A; Kato M; Kinoshita T
CNS Spectr; 2022 Jun; 27(3):369-377. PubMed ID: 33461636
[TBL] [Abstract][Full Text] [Related]
19. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
[TBL] [Abstract][Full Text] [Related]
20. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
